FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Leonard Braden Michael						2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ ACRS ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  10% Owner						
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 08/02/2024											Office below	ficer (give title low)			er (spec w)	ify
65 E CEDAR - SUITE 2						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	(Street) ZIONSVILLE IN 46077													Form filed by One Reporting Person Form filed by More than One Reporting Person						ıg	
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication																	
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															l to	
		Table	· I -	Non-Deriva	tive	Secu	rities	Acq	uir	ed, l	Disp	posed o	of, or	Benefici	iall	y Own	ed				$\neg$
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Co	Transaction Code (Instr.		4. Securities Acqui Disposed Of (D) (In					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Со	de	v	Amo	ount	(A) or (D)	Price	Reporte Transac (Instr. 3		d tion(s)				
Common Stock				08/02/2024				F	P		16	57,544	A	A \$1.2916 <sup>(2)</sup>		14,043,975		I		Holdi BML Invest Partne L.P. <sup>(1)</sup>	etment ers,
Common Stock				08/05/2024				I	P		20	06,025	A	\$1.2443	(3)	14,250,000		I		Holding of BML Investment Partners, L.P <sup>(1)</sup>	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
Derivative   Conversion   Date   E   Security   Or Exercise   (Month/Day/Year)   if			Ex if a			ansaction of ode (Instr. Derivat		ative rities ired sed	Expiration (Month/Dies ed					tle and bunt of urities erlying vative urity (Instr. d 4)	nt		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Owners Form: Direct (I or Indire (I) (Instr	hip of Be O) Ov ect (In	. Nature Indirect eneficial wnership nstr. 4)
				Code	ode V (A) (		(D)	Date D) Exercisa		Expiration ble Date		n Title	Number of Shares								

## **Explanation of Responses:**

- 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- 2. Represents shares purchased in multiple transactions resulting in a weighted average purchase price of \$1.2916 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range
- 3. Represents shares purchased in multiple transactions resulting in a weighted average purchase price of \$1.2443 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.

08/05/2024 Braden Michael Leonard

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.